Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer exec Stephen Williams joins Venaxis board

Is current chief medical officer of SomaLogic

Former Pfizer exec Stephen Williams joins Venaxis boardVenaxis has appointed former Pfizer VP Dr Stephen Williams to its board of directors.

Dr Williams, who is currently chief medical officer at SomaLogic, has years of experience in diagnostic imaging and biomarker discovery, which will benefit Venaxis as it prepares to clear and commercialise its protein biomarker-based assay for appendicitis.

Dr Williams said: "The APPY1 Test is an excellent example of how characterisation of clinically relevant biomarkers can produce useful tools for addressing important diagnostic challenges.

“With the potential to reduce the safety risks associated with current diagnostic imaging techniques in the emergency setting, I believe there is significant clinical need and utility for the APPY1 Test.”

Dr Williams joined SomaLogic in 2009, leading the development of its protein biomarkers and clinical diagnostics.

He joined Pfizer in 1989, and spent 18 years at the company, working in both the UK and US and holding roles that included worldwide head, clinical technology.

In addition, Dr Williams served on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering from 2004 to 2007 and the executive Committee of the Biomarkers Consortium run by the Foundation for NIH from 2005-2007.

23rd April 2013

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

3 reasons why clinical trials will thrive in 2021
It’s not often that a single event can change the trajectory of an entire system, yet that is exactly what has happened to healthcare systems across the world and clinical...
#DemandDiversity: New research on COVID-19 clinical trial perceptions within minorities and high-risk populations
Lack of diversity in clinical trials still remains on of the biggest issues for COVID-19 clinical trials. But despite the growing discussions, calls for change, growing regulatory guidance and much...
Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...

Infographics